Figure 4.

Mutation analysis of CD19 across various cancer types. A. This panel shows that out of 289 cervical squamous cell carcinoma (CESC) samples, 0.69% (2 samples) exhibit alterations, with missense mutations predominantly represented in green. B. This panel presents data from 92 rectum adenocarcinoma (READ) samples, revealing a 2.17% (2 samples) alteration rate, again with missense mutations being the most common. C. This panel also analyzes 92 sarcoma (SARC) samples, indicates that 1.09% (1 sample) have mutations, predominantly missense mutations. D. Tumor mutation burden (TMB) analysis of CD19 in various cancers. E. Microsatellite instability (MSI) analysis of CD19 in various cancers. P-value < 0.05.